Tags : Moderate-to-Severe Plaque Psoriasis


Sun Pharma’s Ilumya Receives Australian Therapeutic Goods Administration (TGA) Approval

Shots: TGA approval is based on P-III reSURFACE data (N=1862) i.e. (reSURFACE 1 and reSURFACE 2) assessing Ilumya 100mg vs PBO or etanercept, showing PASI 75 reduction in psoriasis severity and Physician’s Global Assessment (PGA) score clear or minimal @12wks. after two doses Ilumya (tildrakizumab) 100mg is a SC injection administered q12w post 0 and […]Read More